BioCentury
ARTICLE | Clinical News

Calsed amrubicin: Final Phase II data

August 10, 2009 7:00 AM UTC

Final data from 72 evaluable patients sensitive to previous first-line platinum-based therapy in an open-label, U.S. Phase II trial, showed that amrubicin met the primary endpoint of a significantly h...